Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying RC288, a drug being evaluated for its safety, tolerability, and effectiveness in treating locally advanced unresectable or metastatic malignant solid tumors. The study aims to find the highest safe dose and the recommended dose for further testing while assessing how well the drug works at that dose. This is a Phase III clinical trial sponsored by RemeGen Co., Ltd., involving multiple centers. Participants receive RC288 through intravenous infusion. The study includes six predefined dose levels that increase stepwise in Phase I to determine the maximum tolerated or administered dose. In Phase II, the recommended dose is further tested across various cancer types to evaluate safety and effectiveness. Patients continue treatment until they experience unacceptable side effects, disease progression, or meet criteria for withdrawal. During the study, participants undergo regular assessments including imaging to measure tumor responses, evaluations for adverse events, and monitoring of vital organ functions. Researchers will collect data over 24 months on dose-limiting toxicities, side effect severity, and tumor response rates using established criteria. The trial lasts up to approximately four years with ongoing safety monitoring and efficacy assessments throughout.
Actively Recruiting
Researchers are observing patients who receive Siltartoxatug Injection, also known as Sintetol4, to prevent tetanus following injury. This large-sample, real-world registry aims to document injury and wound conditions and evaluate clinical outcomes related to tetanus prevention. The study focuses on collecting safety information and any adverse reactions after receiving the injection. Participants in this observational study receive Siltartoxatug Injection as part of their tetanus prophylaxis after injury. The study does not involve randomization or comparison groups but follows patients over time to monitor outcomes. A key part of the study is the follow-up at 90 days after administration to assess whether tetanus develops and to record any safety events. During the study, patient injury details and wound conditions will be carefully noted. Safety data will be selectively collected to identify any adverse reactions or serious events linked to Siltartoxatug use. The main outcome measure is the occurrence of tetanus within 90 days post-injection. Participants are followed for this 90-day period to evaluate treatment outcomes and safety.
Actively Recruiting
Researchers are evaluating the safety, tolerability, effectiveness, and how the body processes MRG007 ARR-217 in people with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. This phase I, open-label, multi-center study focuses on patients who have advanced or metastatic solid tumors such as colorectal, gastric, or pancreatic cancer, particularly those who have not responded to or cannot tolerate standard treatments. Participants receive MRG007 alone or combined with Bevacizumab according to the study protocol. The study uses a sequential design and includes dose escalation, confirmation, and expansion phases. Treatments are administered as specified, and the study monitors participants from the first dose through up to 24 months to assess responses and safety. During the study, participants will be closely monitored for various outcomes including dose-limiting toxicities, serious and treatment-related side effects, and tumor response rates. Assessments include physical exams, laboratory tests, and imaging to measure tumor size according to RECIST criteria. Safety monitoring continues for 30 days after the last dose, and overall survival, disease control, and pharmacokinetics are tracked throughout the study period, which may last until December 2030.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.
Actively Recruiting
Researchers are evaluating CNSI-Fe, an innovative anti-cancer drug containing Fe2 loaded on carbon nanoparticles, in people with advanced solid tumors. CNSI-Fe works by regulating a cell death process called ferroptosis and aims to improve cancer treatment through intratumoral injections. This Phase IbIIa study follows an initial Phase I trial where different doses showed promising safety and disease control in various advanced solid tumor patients. Participants will receive CNSI-Fe injections directly into 1 to 3 tumor lesions every two weeks for a total of 4 doses, with the possibility of additional doses if the benefits outweigh risks. The study includes a screening period, treatment period, and follow-up phase. Tumor response and safety will be closely monitored, and injections will stop or switch lesions based on tumor shrinkage or disappearance. During the study, participants will undergo safety checks before each dose and tumor evaluations at specified intervals, including before the third dose, after the fourth dose, and every six weeks thereafter. Follow-up includes safety monitoring 28 days after the last dose and regular checks for disease progression until new treatment, death, or study end. Samples will be collected at scheduled visits to assess safety, drug levels, and anti-tumor effects.
Actively Recruiting
Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.
Actively Recruiting
Researchers are evaluating the efficacy and safety of BR005-036C tablets compared to placebo in adults experiencing acute migraine attacks, including those with or without aura. This phase IIIII, multicenter, randomized, double-blind study aims to better understand how well BR005-036C works to relieve migraine symptoms and how it compares to placebo treatment. Participants are randomly assigned to take one of two doses of BR005-036C oral tablets or a matching placebo tablet. The study assesses the medications effects shortly after dosing, focusing on relief from pain and bothersome symptoms within two hours. The trial includes a treatment period with close monitoring for up to nine days after taking the study drug. During the study, participants will be monitored for migraine pain relief, freedom from symptoms, use of rescue medications, and functional ability after dosing. Researchers will track adverse events and other safety measures throughout the treatment period. The primary outcomes focus on pain freedom and symptom relief two hours after dosing, with additional assessments up to 48 hours. Participants involvement includes medication dosing and follow-up visits to assess their response and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of early PCSK9 inhibitor therapy in adults aged 18 to 80 who have experienced a large-artery atherosclerotic ischemic stroke. The study compares patients treated with evolocumab plus statin therapy to those receiving statin therapy alone, focusing on neurological improvement, lipid reduction, functional outcomes at 90 days, recurrent cardiovascular events, and safety. Participants will be assigned to one of two groups based on their routine clinical care one group will receive evolocumab injections 140 mg every 2 weeks or 420 mg monthly plus daily statins for 90 days, while the other group will receive only daily statin therapy for the same period. The study is conducted across multiple centers and includes baseline, day 7 or hospital discharge, day 30, and day 90 visits for assessments. During the study, participants will undergo evaluations including neurological scales and lipid measurements at scheduled visits. Researchers will monitor functional outcomes using the modified Rankin Scale at 90 days, track early neurological changes, recurrent events, and mortality. Safety follow-up continues through day 90 even if evolocumab treatment stops. Total participation spans approximately 90 days post-stroke onset.
Actively Recruiting
Researchers are conducting an open, single-arm Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary effectiveness of FS-8002, alone and in combination with Toripalimab Injection and chemotherapy, in patients with advanced solid tumors. This study aims to better understand how these therapies work and their potential impact on patients who have not responded to or cannot tolerate standard treatments. Participants will receive FS-8002 injection every three weeks, either alone or combined with Toripalimab Injection, with some also receiving chemotherapy chosen by their doctor. Treatment continues until the patient experiences disease progression, unacceptable side effects, death, loss of follow-up, voluntary withdrawal, or the study ends. The study includes a dose escalation phase with six dose groups involving 42 patients to determine the best dose levels. Throughout the study, participants will be closely monitored with regular assessments of drug levels in the blood, side effects, and tumor responses using recognized criteria. Researchers will evaluate multiple outcomes including maximum tolerated dose, dose-limiting toxicities, adverse events, and various measures of tumor control and patient survival over one to two years. Participants will have ongoing evaluations during treatment and follow-up periods to track safety and effectiveness.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the timing of anemia screening and iron supplementation in women to prevent iron deficiency anemia during late pregnancy. This study compares the effects of screening and treatment before conception versus during the first trimester of pregnancy. The trial aims to understand how early intervention might influence anemia control and maternal and infant health outcomes. Participants in the study are divided into two groups based on township assignment. One group undergoes anemia screening and receives oral iron treatment before conception if needed, including hemoglobin and serum ferritin tests. The other group receives the same screening and treatment during early pregnancy around 12 weeks gestation. Both groups are given oral ferrous succinate with vitamin C and monitored through scheduled blood tests. Throughout the study, women planning to conceive or in early pregnancy will be monitored for hemoglobin and ferritin levels to track anemia status from late pregnancy 28 weeks gestation until delivery. The main outcome measured is the proportion of participants who have iron deficiency anemia during this late pregnancy period. Participants will provide informed consent and complete study procedures during the trial, which runs from 2026 to 2029.
1-10 of 11
1